Gefitinib Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Gefitinib Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 22/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Gefitinib